Siren Biotechnology: A Bold New Approach to Funding Gene Therapy Startups

Innovative Funding for Biotech Startups

Siren Biotechnology, a San Francisco-based gene therapy startup, is venturing into uncharted waters by exploring community investment rounds — a funding method typically associated with tech startups rather than biotech. This comes after securing a $4 million grant and $28 million in venture funding since its inception in 2020.

A Unique Crowdfunding Approach

Last month, Siren announced its plans to pursue regulation crowdfunding, allowing them to sell equity stakes to both accredited and non-accredited investors. This method enables startups to raise up to $5 million in a year through platforms like WeFunder. Although this amount is modest compared to the hundreds of millions typically needed to bring a drug to market, CEO Nicole Paulk sees it as a way to attract diverse investors.

Permission granted by Siren Biotechnology

Siren's Vision and Challenges

Siren is developing a gene therapy that combines elements of cancer immunotherapy, using engineered viruses to deliver cancer-fighting cytokines directly into tumors. Their lead program targets high-grade glioma, which is currently in preclinical testing. The company aims to seek regulatory approval for human trials by the end of the year.

Despite the challenges in raising funds in the current biotech investment climate, Paulk believes crowdfunding could be beneficial for early-stage companies. She emphasizes that even a small amount of cash can significantly impact a preclinical startup.

Engaging the Community

The concept of community investment was inspired by a local CEO who invested in Siren. Paulk is particularly interested in engaging patients and their families, who may have a personal stake in the research, to invest directly in the company rather than just donating to disease foundations.

However, this approach carries risks, as the gene therapy field has faced significant challenges recently, and many drugs do not make it through testing. Siren is transparent about its financial health and operations, offering insights into its business model and future plans.

Early Success in Crowdfunding

Since launching its crowdfunding round, Siren has surpassed the $50,000 minimum threshold required by WeFunder, with several investors already publicly identified. Notably, a lead investor from KMAK Capital expressed confidence in Siren’s innovative science and regulatory navigation.

Paulk is actively sharing her experiences with other biotech founders, aiming to foster a community of support and knowledge sharing within the industry.